Please login to the form below
capivasertib
This page shows the latest capivasertib news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca’s two advanced breast cancer trials meet primary endpoints
CAPItello-291 is a phase 3, double-blind trial evaluating the efficacy of capivasertib in combination with Faslodex versus placebo plus Faslodex in patients with hormone receptor (HR)-positive human epidermal ... Susan Galbraith, executive vice president,
Latest news
-
ICR scientists create AI test to predict cancer drug combinations
Additionally, the test successfully identified combinations that have previously demonstrated potential, including combinations of trametinib and capivasertib in NSCLC lines with EGFR mutations.
-
AZ drug matched to cancer mutation passes phase 2 test
Capivasertib (AZD5363) – an orally-active AKT inhibitor – was tested in 35 patients with breast, endometrial and ovarian cancers who had already been treated with at least three prior regimens and showed ... Meanwhile, this isn’t the first clinical
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Senior Medical Writer
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- The speed of science and the pace of comms
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma Biotherapeutics partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Locus Biosciences announces first patient treated in urinary tract infection trial
- WHY ARE PATIENT SUPPORT PROGRAMMES NOT WORKING?
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
PMHub
Genesis Research
Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...
Latest intelligence
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
